On the Record · Apellis Pharmaceuticals

Apellis Pharmaceuticals acquisitions, on the record

The businesses Apellis Pharmaceuticals bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Potentia Pharmaceuticals, Inc. Word for word“Our filings also include certain U.S. and foreign patents and patent applications relating to methods of treating eye disorders associated with complement activation, which we acquired in the acquisition of the assets of Potentia Pharmaceuticals, Inc., or Potentia.” 10-K for 2023	acquisition	—	—

Deal filings since 2016

2026-05-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-05-14 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2026-03-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-07-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-05-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-11-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-02-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-08-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-07-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-03-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-01-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-11-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-07-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-03-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-01-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-01-04 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-10-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-05-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-01-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-09-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-06-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-03-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-02-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Apellis Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.